Clinical Study of PET/CT and Association With Metabolic Syndrome/Depressive Symptoms in Psoriasis
NCT ID: NCT01661127
Last Updated: 2014-11-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
10 participants
OBSERVATIONAL
2012-06-30
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
FDG-PET/CT represents an innovative approach to studying systemic inflammation in a manner that is sensitive, quantifiable, and anatomically localizable. Also, recent study show that chronic disease such as end stage renal disease with depressive symptoms have decreased cerebral glucose metabolism in several brain areas in F-18-FDG PET/CT. So this protocol was designed to evaluate usefulness of PET/CT to detect systemic inflammation and abnormality of cerebral glucose metabolism and association with metabolic syndrome/major depressive symptoms in patients with psoriasis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Novel PET Radioligand as an Inflammatory Biomarker in Musculoskeletal Conditions
NCT03912428
Molecular Determinants of Persistent Cancer Related Fatigue
NCT01980719
Diagnostic Performance of 18-FDG PET-CT Scores for the Diagnosis of Polymyalgia Rheumatica
NCT06558357
Alterations in Protein Synthesis Rates of Burn Patients Measured Over Time Using PET Scans
NCT00253279
Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease
NCT06203249
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Evaluate PASI score
2. Evaluate comorbidity with metabolic syndrome
* Body mass index(BMI)
* Checking blood pressure
* Checking blood sugar
* Smoking and drinking history
* Checking blood cholesterol level
* Risk factors of cardiovascular disease
3. PET/CT for measuring the extent and site of psoriasis with inflammation
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* at least 18 years old
Exclusion Criteria
* those who take antidepressant
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pusan National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Byung-Soo Kim, Ph D.
Role: STUDY_CHAIR
Pusan National University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of dermatology, Pusan National University Hospital
Busan, Busan, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PNUHDM-psoriasis
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.